Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Fastly Inc (FSLY) Price & Performance

BridgeBio Pharma IncTrade
Fastly IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Fastly Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Fastly Inc trades at $28.5 (market cap $4.58B). The key difference: BridgeBio Pharma Inc is far larger — about 3.6× Fastly Inc's market cap. Which is the better fit depends on your goals.

BBIOFSLY
Market Cap
$16.36B$4.58B
Sector
HealthTechnology
52-Week High
$90.17$33.50
52-Week Low
$47.29$6.85
Enterprise Value
$18.14B$4.65B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Fastly Inc

Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.

Read more on FSLY